Engine Capital Management, Lp Buys 124,797 Shares of Orthofix Medical (NASDAQ:OFIX) Stock

Orthofix Medical Inc. (NASDAQ:OFIX) major shareholder Engine Capital Management, Lp purchased 124,797 shares of the firm’s stock in a transaction on Tuesday, February 24th. The shares were purchased at an average cost of $12.55 per share, for a total transaction of $1,566,202.35. Following the completion of the purchase, the insider directly owned 3,663,133 shares in the company, valued at $45,972,319.15. The trade was a 3.53% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Engine Capital Management, Lp also recently made the following trade(s):

• On Wednesday, February 25th, Engine Capital Management, Lp bought 13,061 shares of Orthofix Medical stock. The shares were purchased at an average price of $12.96 per share, for a total transaction of $169,270.56.

Orthofix Medical Trading Up 2.7%

Shares of OFIX opened at $13.53 on Friday. Orthofix Medical Inc. has a fifty-two week low of $10.24 and a fifty-two week high of $18.66. The company has a market capitalization of $535.79 million, a PE ratio of -5.78 and a beta of 0.78. The stock has a fifty day moving average of $14.08 and a two-hundred day moving average of $14.70. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.38 and a current ratio of 2.45.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings data on Tuesday, February 24th. The medical device company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.50). Orthofix Medical had a negative net margin of 11.21% and a negative return on equity of 20.38%. The business had revenue of $219.91 million during the quarter, compared to analysts’ expectations of $218.72 million. As a group, analysts forecast that Orthofix Medical Inc. will post -2.81 EPS for the current year.

Trending Headlines about Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Engine Capital (a major shareholder) bought shares in two recent transactions — ~124,797 shares at ~$12.55 on Feb. 24 and an additional 13,061 shares at ~$12.96 on Feb. 25 — increasing its stake and signaling confidence from a large institutional holder. Engine Capital purchases OFIX shares
• Neutral Sentiment: Analysts trimmed price targets but kept several constructive ratings: Canaccord cut its target from $24 to $20 (still a “buy”) and others reduced targets modestly; consensus remains mixed (roughly a mid‑teens/$18-ish average target). This lowers upside expectations but does not indicate a broad teardown of the bull case. Analyst notes and price-target changes
• Negative Sentiment: Q4 results missed on EPS: reported ($0.06) vs. $0.44 expected; revenue was roughly in line but margins and ROE were negative — the EPS shortfall triggered investor selling and increased near-term skepticism. Shares down after earnings miss
• Negative Sentiment: Management flagged margin delays and issued revised 2026 guidance that shifts the narrative toward execution risk; until margin recovery and guidance clarity appear, the stock faces headwinds. Narrative shifting: margin delays and guidance

Analysts Set New Price Targets

A number of brokerages have weighed in on OFIX. Canaccord Genuity Group decreased their price target on shares of Orthofix Medical from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday. TD Cowen initiated coverage on Orthofix Medical in a research note on Tuesday, January 27th. They set a “hold” rating and a $14.00 price target for the company. Barrington Research decreased their target price on Orthofix Medical from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Orthofix Medical currently has a consensus rating of “Hold” and an average target price of $18.25.

Institutional Trading of Orthofix Medical

A number of hedge funds have recently made changes to their positions in OFIX. VARCOV Co. acquired a new stake in Orthofix Medical during the 4th quarter valued at $164,000. Juniper Investment Company LLC boosted its holdings in Orthofix Medical by 23.3% in the fourth quarter. Juniper Investment Company LLC now owns 3,510,333 shares of the medical device company’s stock valued at $53,217,000 after purchasing an additional 663,278 shares during the last quarter. Engineers Gate Manager LP grew its stake in Orthofix Medical by 92.6% during the 4th quarter. Engineers Gate Manager LP now owns 85,101 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 40,923 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Orthofix Medical in the 4th quarter valued at approximately $238,000. Finally, Armistice Capital LLC boosted its stake in shares of Orthofix Medical by 18.4% during the 4th quarter. Armistice Capital LLC now owns 2,648,000 shares of the medical device company’s stock valued at $40,144,000 after buying an additional 412,000 shares during the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.